EXEL - Exelixis Inc
IEX Last Trade
26.02
0 0%
Share volume: 1,923,752
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$26.02
0.00
0.00%
View ratios
| Fiscal Date | 2022-07-01 | 2022-09-30 | 2022-12-30 | 2023-03-31 | 2023-06-30 | 2023-09-29 | 2023-12-29 | 2024-03-29 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-01 | 2023-02-07 | 2023-05-09 | 2023-08-01 | 2023-11-01 | 2024-02-06 | 2024-04-30 | |
| Assets | |||||||||
| Total Assets | 2.881 B | 2.961 B | 3.071 B | 3.143 B | 3.142 B | 2.977 B | 2.942 B | 2.804 B | |
| Current Assets | 1.852 B | 1.842 B | 1.619 B | 1.638 B | 1.591 B | 1.443 B | 1.318 B | 1.292 B | |
| Inventories | 33.020 M | 26.711 M | 33.299 M | 29.908 M | 28.635 M | 24.978 M | 17.323 M | 21.106 M | |
| Other Current Assets | 48.281 M | 52.903 M | 62.211 M | 60.654 M | 62.259 M | 66.891 M | 67.926 M | 67.490 M | |
| Short Term Investments | 48.281 M | 52.903 M | 62.211 M | 60.654 M | 62.259 M | 66.891 M | 67.926 M | 67.490 M | |
| Total Receivables | 235.400 M | 215.015 M | 214.784 M | 233.923 M | 232.818 M | 248.113 M | 237.407 M | 240.577 M | |
| Current Cash | 1.535 B | 1.547 B | 1.308 B | 1.313 B | 1.267 B | 1.103 B | 995.302 M | 963.256 M | |
| Total Non-current Assets | 1.030 B | 1.120 B | 1.453 B | 1.506 B | 1.552 B | 1.534 B | 1.624 B | 1.511 B | |
| Property Plant Equipment | 108.529 M | 107.909 M | 110.624 M | 116.212 M | 115.004 M | 121.039 M | 128.731 M | 127.222 M | |
| Other Assets | 279.705 M | 280.008 M | 290.578 M | 289.627 M | 303.523 M | 306.148 M | 342.122 M | 329.278 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 63.684 M | 63.684 M | 63.684 M | 63.684 M | 63.684 M | 63.684 M | 63.684 M | 63.684 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.881 B | 2.961 B | 3.071 B | 3.143 B | 3.142 B | 2.977 B | 2.942 B | 2.804 B | |
| Total liabilities | 490.144 M | 469.970 M | 583.062 M | 588.223 M | 614.530 M | 629.290 M | 678.445 M | 675.744 M | |
| Total current liabilities | 304.521 M | 301.733 M | 324.359 M | 327.597 M | 339.617 M | 376.816 M | 394.277 M | 373.010 M | |
| Accounts Payable | 19.978 M | 30.572 M | 32.667 M | 32.621 M | 25.994 M | 26.450 M | 33.768 M | 26.069 M | |
| Other liabilities | 24.604 M | 8.399 M | 68.533 M | 73.678 M | 80.219 M | 61.616 M | 94.224 M | 101.268 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 24.604 M | 8.399 M | 68.533 M | 73.678 M | 80.219 M | 61.616 M | 94.224 M | 101.268 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 2.391 B | 2.491 B | 2.488 B | 2.555 B | 2.528 B | 2.348 B | 2.264 B | 2.128 B | |
| Common stock | 321.117 M | 322.148 M | 323.257 M | 324.420 M | 324.205 M | 315.496 M | 308.483 M | 300.757 M | |
| Retained earnings | -77.262 M | -4.052 M | -34.225 M | 5.803 M | 11.186 M | -126.049 M | -173.351 M | -258.948 M |